Phase 2, Multicentre, Randomized, Double Blind, 2 Arms Placebo-controlled Study in Adults With Moderate COVID-19 With Gastrointestinal Signs and Symptoms
Latest Information Update: 24 Jun 2024
At a glance
- Drugs Niclosamide (Primary)
- Indications COVID 2019 infections; Gastrointestinal disorders
- Focus Therapeutic Use
- Sponsors Entero Therapeutics; First Wave Bio
Most Recent Events
- 16 May 2024 According to an Entero Therapeutics media release, First Wave Biopharma has changed its name to Entero Therapeutics.
- 04 Feb 2022 Planned End Date changed from 1 Dec 2021 to 20 Jan 2022.
- 04 Feb 2022 Planned primary completion date changed from 1 Aug 2021 to 20 Jan 2022.